Testing MORF-057 for moderate to severe Crohn's disease
Part of Digestive system clinical trials.
This study tests an oral medicine called MORF-057 for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms for those who haven't had success with other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had Crohn's disease symptoms for at least 3 months before joining the study.
- Your Crohn's disease should be moderate to severe, meaning you have daily diarrhea and stomach pain.
- You must have tried at least one previous Crohn's treatment (like steroids, immune drugs, or advanced therapies) that didn't work or caused side effects.
- You cannot have had certain types of colitis other than Crohn's, or have Crohn's only in areas like your mouth or anus.
- You cannot have had more than 3 bowel surgeries or had a large section of bowel removed.
- You cannot have ever taken vedolizumab or similar integrin-blocking medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medication called TAK-279 to see if it can safely reduce inflammation in the bowel for people with moderate to severe Crohn's disease who haven't had success with other treatments.
This study tests a new medicine called SL-325, which may help reduce inflammation in the gut. It is for people with moderate to severe Crohn's disease who have not responded well to other treatments.
This trial tests new targeted therapies for adults with moderate to severe Crohn's disease that hasn't improved with standard treatments. The goal is to see if these drugs can reduce inflammation and improve symptoms.
This trial tests new therapies for people with moderate to severe Crohn's disease or ulcerative colitis. It may help if your standard treatments aren't working well enough.
This study tests an experimental pill, H021, for people with moderate to severe Crohn's disease. It aims to see if H021 can reduce inflammation and improve symptoms. Participants will take the pill or a placebo, and the study will monitor how well it works.
This trial tests a new medicine called brivekimig for people with moderate-to-severe Crohn's disease. It aims to see if the drug can reduce symptoms and inflammation better than standard treatments.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.